Alogliptin, pioglitazone; 12.5mg/15mg, 12.5mg/30mg, 12.5mg/45mg, 25mg/15mg, 25mg/30mg, 25mg/45mg; tabs.
Bladder cancer risk increases with longer duration of use.
After analyzing new data, the FDA again warns that the diabetes drug may be associated with an increased risk for bladder cancer.
A recent meta-analysis reveals that pioglitazone increases the risk of bladder cancer by 22%.
Findings showed that the combination of insulin and pioglitazone lowered all-cause mortality risk, and this combination therapy exerted beneficial effects on noncardiovascular deaths.
But research reveals association with pancreatic and prostate cancer.
Duration- and dose-response associations for pioglitazone; no correlation for rosiglitazone.
Manufacturers of certain drugs approved to treat type 2 diabetes have agreed to add an upgraded "boxed" warning emphasizing that the drugs may cause or worsen heart failure in certain patients.
Combination therapy was effective in lowering the HbA1c independent of sex, ethnicity, BMI, or baseline HbA1c.
News in Brief
A British study of 115,727 patients with type 2 diabetes who became new users of oral hypoglycemic agents from 1988 through 2009.